| Literature DB >> 35694478 |
Yifan Hao1,2, Bo Peng3, Chao Si1,2, Bo Wang3, Chengfeng Luo3, Menghao Chen3, Cheng Luo4, Baijuan Gong4, Zhimin Li3.
Abstract
Malignant tumors are one of the main causes of human death. The clinical treatment of malignant tumors is usually surgery, chemotherapy, radiotherapy, and so forth. Radiotherapy, as a traditional and effective treatment method for cancer, is widely used in clinical practice, but the radiation resistance of tumor cells and the toxic side effects to normal cells are still the Achilles heel of radiotherapy. Multifunctional inorganic high-atom nanomaterials are expected to enhance the effect of tumor radiotherapy. Tungsten and bismuth, which contain elements with high atomic coefficients, have strong X-ray energy attenuation capability. We synthesized Bi2WO6 nanosheets (NSs) using a hydrothermal synthesis method and modified polyvinylpyrrolidone (PVP) on their surface to make them more stable. PVP-Bi2WO6 NSs have a variety of effects after absorbing X-rays (such as the photoelectric effect and Compton effect) and release a variety of particles such as photoelectrons, Compton electrons, auger electrons, and so forth, which can react with organic molecules or water in cells, generate a large number of free radicals, and promote cell apoptosis, thereby improving the effect of radiotherapy. We show through γ-H2AX and DCFH-DA probe analysis experiments that PVP-Bi2WO6 NSs can effectively increase cell DNA damage and reactive oxygen species formation under X-ray irradiation. Clone formation analysis showed that PVP-Bi2WO6 NSs can effectively suppress cell colony formation under X-ray irradiation. These versatile functions endow PVP-Bi2WO6 NSs with enhanced radiotherapy efficacy in animal models. In addition, PVP-Bi2WO6 NSs can also be used as contrast agents for X-ray computed tomography (CT) imaging with obvious effects. Therefore, PVP-Bi2WO6 NSs can be used as CT imaging contrast agents and tumor radiotherapy sensitizers and have potential medical applications.Entities:
Year: 2022 PMID: 35694478 PMCID: PMC9178605 DOI: 10.1021/acsomega.2c01591
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1(a) TEM image of Bi2WO6 NSs. (b) Powder XRD patterns of Bi2WO6 NSs. (c) TEM image of PVP–Bi2WO6 NSs.
Figure 2(a) In vitro cytotoxicity of PVP–Bi2WO6 NSs with different concentrations was tested by CCK-8. (b) In vitro cytotoxicity of PVP–Bi2WO6 NSs with different concentrations was tested by flow cytometry.
Figure 3(a) The apoptosis of CAL27 cells under different treatments was conducted by flow cytometry analysis. (b) The apoptosis of CAL27 cells under different treatments and X-ray dose was conducted by flow cytometry analysis. (c) Clonogenic assay of CAL27 cells under different treatments (X-ray dose: 6 Gy). (d) Survival fraction of CAL27 cells under different treatments (X-ray dose: 6 Gy). (e) Survival fraction of CAL27 cells under different treatments and X-ray doses. **P < 0.01 and ***P < 0.001.
Figure 4(a) ROS detection in CAL27 cells under different treatments by using DCFH-DA as the probe (scale bar is 100 μm). (b) Average signal intensity of DCFH-DA after different treatments. (c) Average signal intensity of γ-H2AX after different treatments. (d) γ-H2AX staining in CAL27 cells under different treatments (scale bar is 50 μm). **P < 0.01 and ***P < 0.001.
Figure 5In vivo synergistic therapy. The mice are divided into four groups: control group, PVP–Bi2WO6 group, X-ray irradiation group, and PVP–Bi2WO6 + X-ray irradiation group. (a) Tumor volume of mice during 18 days. (b) Photographs of tumors at the end of treatment. (c) Photographs of typical mice at the end of treatment. The average tumor volume is 311, 292, 162, and 24 mm3 for each group. (d) H&E staining of tumors at the end of treatment. The scale bar is 100 μm. (e) Average weights of tumors at the end of treatment. (f) Body weight curves of mice during 18 days. ns P > 0.05 (no significant difference) and ***P < 0.001.
Figure 6(a) CT images of diatrizoate meglumine and PVP–Bi2WO6 NSs. (b) HU value of diatrizoate meglumine and PVP–Bi2WO6 NSs in CT imaging at different concentrations. (c) HU value in CT imaging 24 h after injection of diatrizoate meglumine and PVP–Bi2WO6 NSs into the tail vein of mice, respectively.